Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 27.79
NVO's Cash to Debt is ranked higher than
50% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. NVO: 27.79 )
Ranked among companies with meaningful Cash to Debt only.
NVO' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 11.87 Max: N/A
Current: 27.79
Equity to Asset 0.51
NVO's Equity to Asset is ranked lower than
67% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NVO: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
NVO' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.65 Max: 0.73
Current: 0.51
0.42
0.73
Interest Coverage 10.35
NVO's Interest Coverage is ranked lower than
88% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 10.35 )
Ranked among companies with meaningful Interest Coverage only.
NVO' s Interest Coverage Range Over the Past 10 Years
Min: 9.18  Med: 25.51 Max: 884.41
Current: 10.35
9.18
884.41
F-Score: 8
Z-Score: 18.23
M-Score: -2.49
WACC vs ROIC
12.27%
139.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 43.52
NVO's Operating margin (%) is ranked higher than
94% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. NVO: 43.52 )
Ranked among companies with meaningful Operating margin (%) only.
NVO' s Operating margin (%) Range Over the Past 10 Years
Min: 21.38  Med: 30.16 Max: 38.84
Current: 43.52
21.38
38.84
Net-margin (%) 31.97
NVO's Net-margin (%) is ranked higher than
93% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. NVO: 31.97 )
Ranked among companies with meaningful Net-margin (%) only.
NVO' s Net-margin (%) Range Over the Past 10 Years
Min: 16.65  Med: 22.44 Max: 30.13
Current: 31.97
16.65
30.13
ROE (%) 86.01
NVO's ROE (%) is ranked higher than
99% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. NVO: 86.01 )
Ranked among companies with meaningful ROE (%) only.
NVO' s ROE (%) Range Over the Past 10 Years
Min: 21.58  Med: 35.47 Max: 63.92
Current: 86.01
21.58
63.92
ROA (%) 42.23
NVO's ROA (%) is ranked higher than
99% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. NVO: 42.23 )
Ranked among companies with meaningful ROA (%) only.
NVO' s ROA (%) Range Over the Past 10 Years
Min: 14.72  Med: 22.61 Max: 37.03
Current: 42.23
14.72
37.03
ROC (Joel Greenblatt) (%) 196.36
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. NVO: 196.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 35.52  Med: 69.14 Max: 140.48
Current: 196.36
35.52
140.48
Revenue Growth (3Y)(%) 13.20
NVO's Revenue Growth (3Y)(%) is ranked higher than
70% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NVO: 13.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.2  Med: 13.75 Max: 127.6
Current: 13.2
-46.2
127.6
EBITDA Growth (3Y)(%) 16.70
NVO's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. NVO: 16.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.6  Med: 16.55 Max: 130.7
Current: 16.7
-44.6
130.7
EPS Growth (3Y)(%) 18.80
NVO's EPS Growth (3Y)(%) is ranked higher than
77% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NVO: 18.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.6  Med: 20.85 Max: 36.9
Current: 18.8
5.6
36.9
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

NVO Guru Trades in Q1 2015

Tom Gayner 1,075,000 sh (unchged)
Steven Cohen Sold Out
Ruane Cunniff 82,050 sh (-0.17%)
Mario Gabelli 6,700 sh (-0.30%)
Murray Stahl 7,740 sh (-2.11%)
Ken Fisher 12,660,235 sh (-2.91%)
Jim Simons 14,513,600 sh (-7.05%)
» More
Q2 2015

NVO Guru Trades in Q2 2015

Murray Stahl 7,740 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Ruane Cunniff 81,800 sh (-0.30%)
Mario Gabelli 6,545 sh (-2.31%)
Ken Fisher 12,295,864 sh (-2.88%)
Jim Simons 14,087,000 sh (-2.94%)
» More
Q3 2015

NVO Guru Trades in Q3 2015

Murray Stahl 7,827 sh (+1.12%)
Tom Gayner 1,075,000 sh (unchged)
Ruane Cunniff 81,320 sh (-0.59%)
Ken Fisher 11,652,268 sh (-5.23%)
Mario Gabelli 6,170 sh (-5.73%)
Jim Simons 13,171,000 sh (-6.50%)
» More
Q4 2015

NVO Guru Trades in Q4 2015

Mario Gabelli 6,210 sh (+0.65%)
Ken Fisher 11,447,413 sh (-1.76%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Novo Nordisk A/S

Jim Simons' Five Most-Heavily Weighted Holdings Colgate-Palmolive tops the list
More than 30 years ago, Jim Simons (Trades, Portfolio) founded investment firm Renaissance Technologies. Today it is one of the most successful hedge funds in the world. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.00
NVO's P/E(ttm) is ranked higher than
57% of the 376 Companies
in the Global Biotechnology industry.

( Industry Median: 30.34 vs. NVO: 26.00 )
Ranked among companies with meaningful P/E(ttm) only.
NVO' s P/E(ttm) Range Over the Past 10 Years
Min: 12.13  Med: 23.69 Max: 35.76
Current: 26
12.13
35.76
Forward P/E 19.65
NVO's Forward P/E is ranked lower than
56% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.89 vs. NVO: 19.65 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.00
NVO's PE(NRI) is ranked higher than
59% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 31.50 vs. NVO: 26.00 )
Ranked among companies with meaningful PE(NRI) only.
NVO' s PE(NRI) Range Over the Past 10 Years
Min: 12.03  Med: 23.66 Max: 35.76
Current: 26
12.03
35.76
P/B 19.88
NVO's P/B is ranked lower than
99.99% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. NVO: 19.88 )
Ranked among companies with meaningful P/B only.
NVO' s P/B Range Over the Past 10 Years
Min: 3.66  Med: 7.53 Max: 31.9
Current: 19.88
3.66
31.9
P/S 8.15
NVO's P/S is ranked higher than
54% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. NVO: 8.15 )
Ranked among companies with meaningful P/S only.
NVO' s P/S Range Over the Past 10 Years
Min: 2.81  Med: 5.45 Max: 10.99
Current: 8.15
2.81
10.99
PFCF 28.05
NVO's PFCF is ranked higher than
53% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.21 vs. NVO: 28.05 )
Ranked among companies with meaningful PFCF only.
NVO' s PFCF Range Over the Past 10 Years
Min: 12.07  Med: 24.26 Max: 47.01
Current: 28.05
12.07
47.01
POCF 24.25
NVO's POCF is ranked higher than
55% of the 383 Companies
in the Global Biotechnology industry.

( Industry Median: 28.02 vs. NVO: 24.25 )
Ranked among companies with meaningful POCF only.
NVO' s POCF Range Over the Past 10 Years
Min: 9.91  Med: 18.73 Max: 32.48
Current: 24.25
9.91
32.48
EV-to-EBIT 18.84
NVO's EV-to-EBIT is ranked higher than
54% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. NVO: 18.84 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.60 Max: 25.7
Current: 18.84
9.2
25.7
EV-to-EBITDA 17.72
NVO's EV-to-EBITDA is ranked higher than
51% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. NVO: 17.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16.00 Max: 24.7
Current: 17.72
8.2
24.7
PEG 1.52
NVO's PEG is ranked higher than
69% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.61 vs. NVO: 1.52 )
Ranked among companies with meaningful PEG only.
NVO' s PEG Range Over the Past 10 Years
Min: 0.54  Med: 1.18 Max: 1.87
Current: 1.52
0.54
1.87
Shiller P/E 52.42
NVO's Shiller P/E is ranked lower than
51% of the 74 Companies
in the Global Biotechnology industry.

( Industry Median: 52.26 vs. NVO: 52.42 )
Ranked among companies with meaningful Shiller P/E only.
NVO' s Shiller P/E Range Over the Past 10 Years
Min: 22.91  Med: 42.07 Max: 67.69
Current: 52.42
22.91
67.69
Current Ratio 1.34
NVO's Current Ratio is ranked lower than
85% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. NVO: 1.34 )
Ranked among companies with meaningful Current Ratio only.
NVO' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 2.00 Max: 2.45
Current: 1.34
1.04
2.45
Quick Ratio 1.01
NVO's Quick Ratio is ranked lower than
85% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. NVO: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.32 Max: 1.91
Current: 1.01
0.74
1.91
Days Inventory 283.57
NVO's Days Inventory is ranked lower than
83% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 124.17 vs. NVO: 283.57 )
Ranked among companies with meaningful Days Inventory only.
NVO' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 303.04 Max: 343.56
Current: 283.57
246.45
343.56
Days Sales Outstanding 47.78
NVO's Days Sales Outstanding is ranked higher than
66% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. NVO: 47.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.24 Max: 53.6
Current: 47.78
45.09
53.6
Days Payable 90.08
NVO's Days Payable is ranked higher than
67% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 57.61 vs. NVO: 90.08 )
Ranked among companies with meaningful Days Payable only.
NVO' s Days Payable Range Over the Past 10 Years
Min: 59.75  Med: 86.55 Max: 124.07
Current: 90.08
59.75
124.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.49
NVO's Dividend Yield is ranked higher than
53% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. NVO: 1.49 )
Ranked among companies with meaningful Dividend Yield only.
NVO' s Dividend Yield Range Over the Past 10 Years
Min: 0.79  Med: 1.51 Max: 2.47
Current: 1.49
0.79
2.47
Dividend Payout 0.39
NVO's Dividend Payout is ranked lower than
62% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. NVO: 0.39 )
Ranked among companies with meaningful Dividend Payout only.
NVO' s Dividend Payout Range Over the Past 10 Years
Min: 0.51  Med: 1.30 Max: 1.85
Current: 0.39
0.51
1.85
Dividend Growth (3y) 46.20
NVO's Dividend Growth (3y) is ranked higher than
90% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NVO: 46.20 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVO' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 23.00 Max: 49.4
Current: 46.2
0
49.4
Forward Dividend Yield 1.49
NVO's Forward Dividend Yield is ranked higher than
51% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. NVO: 1.49 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 7.11
NVO's Yield on cost (5-Year) is ranked higher than
93% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. NVO: 7.11 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.74  Med: 7.16 Max: 11.7
Current: 7.11
3.74
11.7
3-Year Average Share Buyback Ratio 2.60
NVO's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 531 Companies
in the Global Biotechnology industry.

( Industry Median: -9.90 vs. NVO: 2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.3  Med: 2.40 Max: 49.1
Current: 2.6
-92.3
49.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 28.60
NVO's Price/Tangible Book is ranked lower than
90% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NVO: 28.60 )
Ranked among companies with meaningful Price/Tangible Book only.
NVO' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.14  Med: 6.44 Max: 31.53
Current: 28.6
3.14
31.53
Price/Projected FCF 3.55
NVO's Price/Projected FCF is ranked lower than
53% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 3.23 vs. NVO: 3.55 )
Ranked among companies with meaningful Price/Projected FCF only.
NVO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.41  Med: 3.01 Max: 82.77
Current: 3.55
1.41
82.77
Price/DCF (Earnings Based) 0.92
NVO's Price/DCF (Earnings Based) is ranked higher than
82% of the 39 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. NVO: 0.92 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.62
NVO's Price/Median PS Value is ranked lower than
75% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 1.62 )
Ranked among companies with meaningful Price/Median PS Value only.
NVO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 0.83 Max: 1.91
Current: 1.62
0.14
1.91
Price/Peter Lynch Fair Value 1.22
NVO's Price/Peter Lynch Fair Value is ranked higher than
72% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 1.76 vs. NVO: 1.22 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NVO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.07  Med: 0.97 Max: 1.55
Current: 1.22
0.07
1.55
Price/Graham Number 5.74
NVO's Price/Graham Number is ranked lower than
71% of the 300 Companies
in the Global Biotechnology industry.

( Industry Median: 3.20 vs. NVO: 5.74 )
Ranked among companies with meaningful Price/Graham Number only.
NVO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.58  Med: 2.61 Max: 6.74
Current: 5.74
1.58
6.74
Earnings Yield (Greenblatt) (%) 5.27
NVO's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. NVO: 5.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 6.00 Max: 10.8
Current: 5.27
3.9
10.8
Forward Rate of Return (Yacktman) (%) 27.15
NVO's Forward Rate of Return (Yacktman) (%) is ranked higher than
74% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.48 vs. NVO: 27.15 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.7  Med: 23.10 Max: 35.6
Current: 27.15
1.7
35.6

More Statistics

Revenue(Mil) $14745
EPS $ 1.86
Beta0.35
Short Percentage of Float0.22%
52-Week Range $41.87 - 60.34
Shares Outstanding(Mil)2650.00

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 15,694 16,609 17,566 19,512
EPS($) 1.91 2.27 2.42 2.73
EPS without NRI($) 1.91 2.27 2.42 2.73

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NONOF.USA,
Novo-Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was approved in the United States in December 2014. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. On December 23, 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product will be Saxenda and launch is planned for the first half of 2015. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. In 2014 the Company announced that all activities within inflammation will be discontinued. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the major European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Algeria, Turkey, Australia, India, Argentina, Brazil and Russia.
» More Articles for NVO

Headlines

Articles On GuruFocus.com
Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
Value Investing in BioPharma Nov 18 2015 
Jim Simons' Five Most-Heavily Weighted Holdings Oct 21 2015 
Ken Fisher Reduces Stake in Toyota, Increases Position in Anheuser-Busch Oct 20 2015 
Jim Simons and Ken Fisher Decrease Exposure on Novo Nordisk A/S Sep 14 2015 
Nintai Returns: Q2 2015 Jul 01 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 

More From Other Websites
Novo Nordisk A/S Earnings Analysis: 2015 By the Numbers Feb 05 2016
Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues Feb 04 2016
[$$] Novo Nordisk lowers earnings targets as drug price pressure grows Feb 03 2016
Novo Nordisk CEO Sees Limited Scope for U.S. Price Increases Feb 03 2016
[$$] Novo Nordisk Shares Plunge on Profit Growth Forecast Feb 03 2016
Drugmaker Novo surprises with long-term profit target cut Feb 03 2016
Novo Nordisk CEO: Optimism on Increased U.S. Access Feb 03 2016
More Losses for Europe Stocks as Banks Fall, Earnings Disappoint Feb 03 2016
Novo Nordisk Quarterly Profit Misses Estimates on Victoza Feb 03 2016
China’s diabetes boom promises $23 billion pot for drug makers Jan 30 2016
Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded... Jan 29 2016
How Recent Events Could Affect Novo Nordisk’s Earnings Jan 26 2016
Novo Nordisk A/S - aktietilbagekøbsprogram Jan 25 2016
Novo Nordisk A/S - Share repurchase programme Jan 25 2016
How Is Novo Nordisk’s Position in the Diabetes Segment? Jan 18 2016
What to Expect from Novo Nordisk’s 4Q15 Earnings Jan 18 2016
Novo Nordisk A/S - Aktietilbagekøbsprogram Jan 18 2016
Novo Nordisk A/S - Share repurchase programme Jan 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK